Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene CTNNB1
Variant S33L
Impact List missense
Protein Effect unknown
Gene Variant Descriptions CTNNB1 S33L lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). S33L has been identified in the scientific literature (PMID: 32099073), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, May 2024).
Associated Drug Resistance
Category Variants Paths

CTNNB1 mutant CTNNB1 S33L

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_001098210.2
gDNA chr3:g.41224609_41224610delTCinsCT
cDNA c.97_98delTCinsCT
Protein p.S33L
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
XM_017005738 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_047447477.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_024453356.2 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
NM_001098210 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_017005738.2 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
NM_001904 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_017005738.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_006712985.2 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_024453356.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
NM_001098209 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
NM_001098209.2 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
NM_001098210.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_024453357.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_006712985 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
NM_001904.4 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
NM_001098210.2 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_047447483.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_047447481.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_005264886 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
NM_001904.3 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_047447480.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_006712985.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_047447478.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_024453358.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
XM_047447479.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38
NM_001098209.1 chr3:g.41224609_41224610delTCinsCT c.97_98delTCinsCT p.S33L RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CTNNB1 mutant colorectal cancer sensitive BC21 Preclinical Actionable In a preclinical study, BC21 inhibited growth and viability of a colorectal cancer cell line with a CTNNB1 mutation and increased beta-catenin expression in culture (PMID: 22224445). 22224445
CTNNB1 mutant desmoid tumor not applicable N/A Guideline Diagnostic CTNNB1 mutations aid the diagnosis of desmoid tumor (NCCN.org). detail...
CTNNB1 mutant hepatocellular carcinoma sensitive PMED-1 Preclinical Actionable In a preclinical study, PMED-1 decreased Wnt expression and decreased proliferation of hepatocellular carcinoma cells with Ctnnb1 mutations (PMID: 24819961). 24819961
CTNNB1 mutant medulloblastoma not applicable N/A Guideline Prognostic WNT-driven medulloblastomas, characterized by CTNNB1 or APC mutations, are associated with favorable prognosis (NCCN.org). detail...
CTNNB1 mutant hepatocellular carcinoma predicted - sensitive WNTinib Preclinical - Cell culture Actionable In a preclinical study, WNTinib inhibited Ezh2 phosphorylation and viability in a hepatocellular carcinoma cell line harboring a deletion of CTNNB1 exons in culture (PMID: 37537299). 37537299
CTNNB1 mutant endometrial cancer predicted - sensitive Cabozantinib Case Reports/Case Series Actionable In a Phase II (NCI9322/PHL86) trial, Cometriq (Cabometyx, cabozantinib) treatment resulted in a response rate of 40% (4/10) and a 12-week progression-free survival rate of 70% (7/10) in patients with endometrial cancer harboring CTNNB1 mutations, with a median PFS of 7.6 months (PMID: 31992589; NCT01935934). 31992589
CTNNB1 mutant endometrial cancer predicted - sensitive Temsirolimus Phase II Actionable In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.46) but not response rate (response difference 0.00) in advanced endometrial cancer patients harboring CTNNB1 mutations (PMID: 27016228). 27016228